1. From the Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco/Mt. Zion Cancer Center, University of California (MVM, EPE, SRH, DPL, PRC), San Francisco, California, and TAP Pharmaceutical Products, Inc. (SSM), Lake Forest, Illinois